Clinical trials: Schizo-Affective Disorder
Schizophrenia, Pediatric
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT04779177
- Testing
- Lumateperone 42 mg, Lumateperone 28 mg
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective Disorder
Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation
The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) is effective in remediating cognitive deficits while also improving functionality in Veterans with schizophrenia.
- Trial name
- NCT03037983
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00337662
- Testing
- olanzapine, risperidone
- Where
- 34 sites in United States, Argentina and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Psychosis, Schizophrenia
Levetiracetam in Early Psychosis
In order to establish target engagement and identify an effective dose the investigators will conduct a placebo-controlled single-dose parallel group trial of levetiracetam 185 mg and 500 mg in 24 medication-naïve early psychosis…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
- Trial name
- NCT03129360
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Psychosis, Substance Use
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT05380583
- Testing
- CRAFT-EP, TAU
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia, Hallucinations
Transcranial Magnetic Stimulation for "Voices"
This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00308997
- Testing
- 1-hertz Repetitive Transcranial Magnetic Stimulation, Active 1-Hertz Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Building Employment Skills Through Therapy for Veterans
Schizophrenia/Schizoaffective Disorder is associated with serious problems with cognitive skills, social skills, and functional skills (like employment).
- Trial name
- BESTVet (NCT01992913)
- Testing
- integrated Cognitive Behavioral Therapy, Usual Care, Computerized cognitive remediation (CCR)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life
Purpose: To develop and test the feasibility of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring, and determine the effectiveness of this intervention on the physical and mental…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder
- Trial name
- PACE-life (NCT03757988)
- Testing
- Exercise Intervention- PACE-Life
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder, Schizophrenia
Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
Approximately 60 chronic smokers with bipolar disorder, schizophrenia or schizoaffective disorder who are motivated to try to quit smoking will be randomized to receive smoking cessation treatment with the FDA-approved…
- Conditions
- Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Nicotine Dependence
- Trial name
- NCT04011280
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, San Diego
Psychosis, Substance Use
Families With Substance Use and Psychosis: A Pilot Study
The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT04284813
- Testing
- CRAFT-FT
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia Schizoaffective, Schizophrenia
TMS Related Biomarker Assessments
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active and sham repetitive transcranial magnetic stimulation (rTMS) in separate sessions.
- Trial name
- NCT05660018
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Remediation of Working Memory in Schizophrenia
The primary aim of the study is to test the efficacy of a novel cognitive remediation intervention that targets working memory-related functions.
- Trial name
- NCT00995553
- Testing
- Cognitive Remediation, Computer Skills
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Insomnia, Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life.
- Conditions
- Insomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
- Trial name
- NCT00645944
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Major Depression, Bipolar Depression
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).
- Conditions
- Major Depression, Bipolar Depression, Schizoaffective Disorder
- Trial name
- Galantamine (NCT00566735)
- Testing
- Razadyne
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital